Hofseth BioCare ASA
HOFBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.34 | 0.24 | -1.54 | -1.46 |
| FCF Yield | -2.97% | -1.66% | -5.21% | -4.17% |
| EV / EBITDA | -9.03 | -15.03 | -13.23 | -28.27 |
| Quality | ||||
| ROIC | -48.76% | -31.85% | -51.00% | -42.41% |
| Gross Margin | 34.13% | 22.67% | 23.67% | 26.36% |
| Cash Conversion Ratio | 0.08 | -0.03 | 0.33 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 28.81% | 30.53% | 20.26% | 8.93% |
| Free Cash Flow Growth | -22.92% | 82.05% | 36.76% | 14.26% |
| Safety | ||||
| Net Debt / EBITDA | -2.14 | -4.14 | -0.77 | -1.05 |
| Interest Coverage | -7.22 | -13.59 | -12.92 | -12.62 |
| Efficiency | ||||
| Inventory Turnover | 3.03 | 1.83 | 0.79 | 0.71 |
| Cash Conversion Cycle | -54.45 | 94.14 | -73.40 | -95.24 |